257 related articles for article (PubMed ID: 36352896)
1. What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association.
Allaire M; Bruix J; Korenjak M; Manes S; Maravic Z; Reeves H; Salem R; Sangro B; Sherman M
JHEP Rep; 2022 Dec; 4(12):100578. PubMed ID: 36352896
[TBL] [Abstract][Full Text] [Related]
2. Treatment algorithms for managing hepatocellular carcinoma.
Saraswat VA; Pandey G; Shetty S
J Clin Exp Hepatol; 2014 Aug; 4(Suppl 3):S80-9. PubMed ID: 25755616
[TBL] [Abstract][Full Text] [Related]
3. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).
Mukund A; Bhardwaj K; Choudhury A; Sarin SK
J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846
[TBL] [Abstract][Full Text] [Related]
4. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.
Li H; Liang C; Kuang D; Huang G; Zhang M; Chen P; Zheng Q; Xu W; Ren J; Han X; Duan X
Cancer Biol Ther; 2023 Dec; 24(1):2166335. PubMed ID: 36751709
[TBL] [Abstract][Full Text] [Related]
5. Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective.
Narayanan A; Garza-Berlanga A; Lopera J
Ann Palliat Med; 2023 Nov; 12(6):1244-1259. PubMed ID: 37574584
[TBL] [Abstract][Full Text] [Related]
6. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
7. The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.
Kumar A; Acharya SK; Singh SP; Saraswat VA; Arora A; Duseja A; Goenka MK; Jain D; Kar P; Kumar M; Kumaran V; Mohandas KM; Panda D; Paul SB; Ramachandran J; Ramesh H; Rao PN; Shah SR; Sharma H; Thandassery RB;
J Clin Exp Hepatol; 2014 Aug; 4(Suppl 3):S3-S26. PubMed ID: 25755608
[TBL] [Abstract][Full Text] [Related]
8. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
9. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
10. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS.
Fan W; Guo J; Zhu B; Wang S; Yu L; Huang W; Fan H; Li F; Wu Y; Zhao Y; Wang Y; Xue M; Wang H; Li J
Eur Radiol; 2021 Nov; 31(11):8291-8301. PubMed ID: 33893536
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma.
Razi M; Safiullah S; Gu J; He X; Razi M; Kong J
J Interv Med; 2022 Feb; 5(1):10-14. PubMed ID: 35586278
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity.
Lewis S; Dawson L; Barry A; Stanescu T; Mohamad I; Hosni A
JHEP Rep; 2022 Aug; 4(8):100498. PubMed ID: 35860434
[TBL] [Abstract][Full Text] [Related]
13. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
14. Early Hepatocellular Carcinoma Treated by Radiofrequency Ablation-Mid- and Long-Term Outcomes.
Mukund A; Vats P; Jindal A; Patidar Y; Sarin SK
J Clin Exp Hepatol; 2020; 10(6):563-573. PubMed ID: 33311893
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
Zhu D; Yuan D; Wang Z; Chen S
Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken.
Jearth V; Patil PS; Mehta S; Sundaram S; Seth V; Goel M; Patkar S; Bal M; Rao V
J Clin Exp Hepatol; 2022; 12(3):841-852. PubMed ID: 35677513
[TBL] [Abstract][Full Text] [Related]
17. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
18. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
